ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Dec 29, 2021--
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference. The presentation is scheduled for 9:00am ET on January 12, 2022.
Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 9:20am ET.
A webcast of the presentation and question-and-answer session will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20211229005002/en/
CONTACT: INVESTOR RELATIONS AND MEDIA
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICAL ONCOLOGY
SOURCE: ImmunoGen, Inc.
Copyright Business Wire 2021.
PUB: 12/29/2021 04:30 PM/DISC: 12/29/2021 04:32 PM